Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732075) titled 'Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis' on July 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Onconic Therapeutics Inc.
Condition:
Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Intervention:
Drug: JP-1366 10 mg
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 1, 2026
Target Sample Size: 384
To know more, visit htt...